These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 6200742)

  • 21. [Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
    Stahnke K; Ritter J; Schellong G; Beck JD; Kabisch H; Lampert F; Creutzig U
    Klin Padiatr; 1992; 204(4):253-7. PubMed ID: 1518261
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Analysis of the therapeutic efficacy and prognostic factors of intensive chemotherapy in 91 patients with acute nonlymphoblastic leukemia].
    Bian SG; Hao YS; Wang ZC
    Zhonghua Nei Ke Za Zhi; 1990 Jan; 29(1):22-5, 60. PubMed ID: 2401166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High remission-induction rate in acute myeloid leukaemia.
    Gale RP; Cline MJ
    Lancet; 1977 Mar; 1(8010):497-9. PubMed ID: 65605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAD-induction therapy for 175 adults with acute myeloid leukemia, followed by consolidation and maintenance therapy. The joint study of Ulm and Tübingen.
    Link H; Kurrle E; Frauer HM; Heil G; Heimpel H; Waller HD; Ostendorf P; Wilms K; Hoelzer D
    Onkologie; 1986 Jun; 9(3):135-8. PubMed ID: 3528958
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Amsacrine, cytarabine and thioguanine (AAT) versus daunorubicin, cytarabine, thioguanine (DAT) in adults with untreated acute non-lymphoblastic leukemia (ANLL). Austrian-German results.
    Linkesch W; Michlmayr G; Gerhartz H; Illinger H; König H; Düllmann J; Keilhauer R; Moldrzyk D
    Onkologie; 1989 Feb; 12(1):8-10. PubMed ID: 2654791
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progress in acute myelogenous leukemia.
    Gale RP
    Cancer Treat Rep; 1981; 65 Suppl 4():87-92. PubMed ID: 7049383
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term outcome of high-dose cytarabine-based consolidation chemotherapy for adults with acute myelogenous leukemia.
    Schiller G; Gajewski J; Territo M; Nimer S; Lee M; Belin T; Champlin R
    Blood; 1992 Dec; 80(12):2977-82. PubMed ID: 1467513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Etoposide in remission induction of adult acute myeloid leukemia.
    Leoni F; Ciolli S; Patriarchi S; Morfini M; Rossi Ferrini P
    Acta Haematol; 1990; 83(2):82-5. PubMed ID: 2106200
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prospective comparative study of bone marrow transplantation and postremission chemotherapy for childhood acute myelogenous leukemia. The Associazione Italiana Ematologia ed Oncologia Pediatrica Cooperative Group.
    Amadori S; Testi AM; Aricò M; Comelli A; Giuliano M; Madon E; Masera G; Rondelli R; Zanesco L; Mandelli F
    J Clin Oncol; 1993 Jun; 11(6):1046-54. PubMed ID: 8501490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Remission induction and postremission therapy in acute myelogenous leukemia: British MRC Study.
    Rees JK; Gray RG
    Haematol Blood Transfus; 1990; 33():243-8. PubMed ID: 1691131
    [No Abstract]   [Full Text] [Related]  

  • 31. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes.
    Krug U; Röllig C; Koschmieder A; Heinecke A; Sauerland MC; Schaich M; Thiede C; Kramer M; Braess J; Spiekermann K; Haferlach T; Haferlach C; Koschmieder S; Rohde C; Serve H; Wörmann B; Hiddemann W; Ehninger G; Berdel WE; Büchner T; Müller-Tidow C; ;
    Lancet; 2010 Dec; 376(9757):2000-8. PubMed ID: 21131036
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized comparison of maintenance treatment with androgens, immunotherapy, and chemotherapy in adult acute myelogenous leukemia. A Leukemia-Lymphoma Group Trial of the EORTC.
    Hayat M; Jehn U; Willemze R; Haanen C; Zittoun R; Monconduit M; Lowenberg B; Stryckmans P; Peetermans M; De Cataldo F
    Cancer; 1986 Aug; 58(3):617-23. PubMed ID: 3524789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy of adult acute myeloid leukaemia.
    Suri R; Kueh YK; Han P; Tan YO
    Ann Acad Med Singap; 1990 Mar; 19(2):175-7. PubMed ID: 2346291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intensive consolidation chemotherapy versus standard consolidation maintenance in acute myelogenous leukemia (AML) in first remission. An EORTC/GIMEMA phase III trial (AML8 B). The EORTC Leukemia Cooperative Group and the GIMEMA Group.
    Zittoun R; Liso V; Mandelli F; Rotoli B; de Witte T; Gattringer C; Resegotti L; Caronia F; Leoni P; Petti MC
    Leukemia; 1992; 6 Suppl 2():76-7. PubMed ID: 1578949
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute nonlymphocytic leukemia in adults: results obtained with TAD remission induction therapy.
    Witteveen EO; Verdonck LF; Nieuwenhuis HK; Dekker AW
    Haematol Blood Transfus; 1990; 33():309-13. PubMed ID: 2323635
    [No Abstract]   [Full Text] [Related]  

  • 36. Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: a Southwest Oncology Group study.
    Bigelow CL; Kopecky K; Files JC; Head D; Lipschitz DA; Grever M; Appelbaum FR
    Am J Hematol; 1995 Apr; 48(4):228-32. PubMed ID: 7717369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized study of intermediate versus conventional-dose cytarabine as intensive induction for acute myelogenous leukaemia.
    Schiller G; Gajewski J; Nimer S; Territo M; Ho W; Lee M; Champlin R
    Br J Haematol; 1992 Jun; 81(2):170-7. PubMed ID: 1643014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre study on intensive induction and consolidation therapy in acute myelogenous leukaemia.
    Kurrle E; Ehninger G; Freund M; Heil G; Hoelzer D; Link H; Mitrou PS; Ohl S; Queisser W; Schlimok G
    Blut; 1988 May; 56(5):233-6. PubMed ID: 3285914
    [No Abstract]   [Full Text] [Related]  

  • 39. [A regimen of DATV in the treatment of acute nonlymphocytic leukemia with high complete remission rate].
    Lou FD; Zhou Q; Meng FY
    Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):146-8, 187. PubMed ID: 1395925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study.
    Vogler WR; Velez-Garcia E; Weiner RS; Flaum MA; Bartolucci AA; Omura GA; Gerber MC; Banks PL
    J Clin Oncol; 1992 Jul; 10(7):1103-11. PubMed ID: 1607916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.